HTB http://i-base.info/htb HIV treatment research reports Mon, 21 May 2012 16:35:59 +0000 http://backend.userland.com/rss092 en 13th International workshop on Clinical Pharmacology of HIV Therapy 16–18 April 2012, Barcelona http://i-base.info/htb/16536 Studies on pipeline ARVs: Quad, evitegravir/cobicistat, cobisistat, GSK1265744, BMS986001 dolutegravir, GSK-1265744, long acting formulations (monthly injections): rilpivirine-LA, raltegravir and patient views http://i-base.info/htb/16538 Interactions between malaria drugs and etravirine or darunavir/r http://i-base.info/htb/16541 No interaction between antimalarial amodiaquine and nevirapine http://i-base.info/htb/16544 Atazanavir/ritonavir and voriconazole not to be coadministered http://i-base.info/htb/16547 Pharmacokinetics of atazanavir/ritonavir plus raltegravir http://i-base.info/htb/16551 Milk thistle (silymarin) and darunavir/ritonavir http://i-base.info/htb/16553 Echinacea and etravirine http://i-base.info/htb/16560 Warfarin and ARVs: impact of African American race and ritonavir http://i-base.info/htb/16562 18th Annual Conference of the British HIV Association (BHIVA), 18-20 April 2012, Birmingham, UK http://i-base.info/htb/16419 Oral PrEP acceptable to at least 50% of HIV negative gay men http://i-base.info/htb/16466 Recent infections common in UK; 30% gay men aged 15-25 infected within a year of diagnosis http://i-base.info/htb/16491 One third of HIV positive people at five UK clinics have symptomatic depression: link to adherence and viral suppression – 40% cases are untreated http://i-base.info/htb/16422 Hodgkins Lymphoma: survival normalises to HIV negative rates despite more advanced disease at diagnosis http://i-base.info/htb/16425 Promising outcomes from laser ablative treatment of AIN2/3 to prevent anal cancer http://i-base.info/htb/16431 KS in the HAART era includes patients with high CD4 and suppressed viral load: importance of KS chemotherapy for some patients in addtion to ART http://i-base.info/htb/16434 3rd vs 4th generation HIV testing: almost half of UK clinics out of step with national guidelines http://i-base.info/htb/16437 Case reports of complications from ketamine use in two MSM on ritonavir-based combinations http://i-base.info/htb/16439 Intranasal and topical corticosteroids and risk of Cushing’s symptoms in HIV patients on ritonavir-based combinations http://i-base.info/htb/16441 Outcomes from switches to atazanavir/r in London http://i-base.info/htb/16527 Intimate partner violence towards HIV positive women in the UK http://i-base.info/htb/16529 Global action over the challenge to India’s patent laws http://i-base.info/htb/16269 19th Conference on Retroviruses and Opportunistic Infections (CROI), 5–8 March 2012, Seattle http://i-base.info/htb/16285 Cure research takes centre stage: proof of concept for activating the latent reservoir http://i-base.info/htb/16287 Quad fixed-dose integrase combination: phase 3 studies at week 48 http://i-base.info/htb/16289 Dolutegravir studies continue to show promise http://i-base.info/htb/16291 Tenofovir prodrug: 10 day monotherapy study sets dose at 25 mg for easier coformulation http://i-base.info/htb/16295 Paediatric formulations of ARVs: including an exciting new class http://i-base.info/htb/16308 Lower malaria risk in children receiving lopinavir/ritonavir-based compared to NNRTI-based ART http://i-base.info/htb/16313 High prevalence of d4T-associated lipodystrophy including lipoatrophy in children http://i-base.info/htb/16318 Lopinavir/ritonavir monotherapy in children http://i-base.info/htb/16321 Stopping treatment after early ART in infants http://i-base.info/htb/16324 Supplement: i-Base Introduction to Combination Therapy http://i-base.info/htb/16284 Volume 13 Number 3/4 March/April 2012 http://i-base.info/htb/16282 PrEP: PK modeling of daily TDF/FTC (Truvada) provides close to 100% protection against HIV infection http://i-base.info/htb/16327 Risk of HIV reinfection may be similar to risk of initial HIV infection http://i-base.info/htb/16330 Case report: homozygous CCR5 delta-32 protection overcome by infection with X4 virus http://i-base.info/htb/16332 No association between atazanavir and MI or stroke in D:A:D study http://i-base.info/htb/16334 Hepatitis C coinfection studies http://i-base.info/htb/16336 Herpes Zoster vaccine safe and effective in HIV positive people http://i-base.info/htb/16280 High dose flu vaccine improves antibody responses in HIV positive people http://i-base.info/htb/16277 Dolutegravir Expanded Access Programme http://i-base.info/htb/16274 FDA approves etravirine for treatment-experienced children 6 to 18 years of age and new scored 25 mg tablet for paediatric dosing http://i-base.info/htb/16271 Why global health activists are fired up about Novartis http://i-base.info/htb/16267 Obama’s global, domestic & HIV research budget backslides on existing commitments http://i-base.info/htb/16265 FDA reject capsaicin patch for HIV-related neuropathy http://i-base.info/htb/16263 US HHS adult treatment guidelines updated (March 2012) http://i-base.info/htb/16261 FDA warning of drug interactions between boceprevir and some HIV protease inhibitors http://i-base.info/htb/16259 Free comic book for HIV positive children about CD4, viral load and ARV treatment http://i-base.info/htb/16253 Free full text online articles http://i-base.info/htb/16248 Volume 13 Number 3/4 March/April 2012 PDF http://i-base.info/htb/16244 2nd International Workshop on HIV & Women, 9-10 January 2012, Bethesda, USA http://i-base.info/htb/16128 Similar efficacy and a few gender related differences in side effects with rilpivirine vs efavirenz at 96-weeks http://i-base.info/htb/16126 Volume 13 Number 1/2 January/February 2012 http://i-base.info/htb/16024 The effect of BMI on efficacy, safety and tolerability of lopinavir/r in women http://i-base.info/htb/16124 Hormonal contraception and higher risk of non-AIDS-defining events in Nashville cohort http://i-base.info/htb/16122 Poorer adherence and loss to follow up in Kenyan women who are pregnant when enrolled to ART programmes http://i-base.info/htb/16119 5th HIV Persistence Workshop on HIV Reservoirs, 6-9 December 2011, West Indies http://i-base.info/htb/16116 Workshop report and commentary http://i-base.info/htb/16112 Nevirapine prolonged release (PR) once-daily formulation available in the UK http://i-base.info/htb/16110 Etravirine 200 mg formulation available in UK http://i-base.info/htb/16108 Tenofovir label extended to paediatric indication http://i-base.info/htb/16106 FDA approve US paediatric dose for raltegravir http://i-base.info/htb/16103 FDA approve paediatric dose for darunavir http://i-base.info/htb/16101 Efavirenz dose increase to 800 mg QD with rifampin in patients >50 kg http://i-base.info/htb/16098 FDA approval of generic ARVs http://i-base.info/htb/16096 Disastrous warning for global HIV programmes in 2012 http://i-base.info/htb/16094 Janssen block Patent Pool access to darunavir, rilpivirine and etravrine http://i-base.info/htb/16092 UNITAID continues funding the Patent Pool, paediatric HIV medicines and malaria http://i-base.info/htb/16089 Michel Kazatchkine resigns from Global Fund: Gabriel Jaramillo, Brazilian banker, to serve as general manager http://i-base.info/htb/16087 Call to Action on Global Fund restriction to new funding to 2014 http://i-base.info/htb/16084 Analysis of why the Global Fund cancelled Round 11 http://i-base.info/htb/16082 Reaction to the Global Fund’s decisions on Round 11 and grant renewals http://i-base.info/htb/16078 Activists oppose Gates Foundation funding study using low dose d4T http://i-base.info/htb/16076 Delaying ART in childhood can reduce long-term CD4 count in adulthood http://i-base.info/htb/16073 No increased risk of non-AIDS deaths from cumulative use of ART in EuroSIDA cohort http://i-base.info/htb/16071 Need for expanded access to two promising MDR TB drugs http://i-base.info/htb/16069 Interactions between nevirapine and antimalarials (artemether and lumefantrine) http://i-base.info/htb/16067 Interactions between antiretrovirals and complementary and African traditional medicines http://i-base.info/htb/16065 Drug interactions between sirolimus (rapamycin) and ARVs http://i-base.info/htb/16063 Supplement: HIV testing and risks of sexual transmission http://i-base.info/htb/16029 Draft BHIVA ARV treatment guidelines online for comment until 5 March http://i-base.info/htb/16058 Contraceptive failure with etonogestrel implants and efavirenz: case reports http://i-base.info/htb/16060 BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011 http://i-base.info/htb/16056 Draft BHIVA pregnancy guidelines online for comment until 5 March http://i-base.info/htb/16155 NICE guidance on increasing the uptake of HIV testing http://i-base.info/htb/16053 London Commissioning: new announcements http://i-base.info/htb/16051 Testosterone: A man’s guide: practical tips for boosting physical, mental and sexual vitality; by Nelson Vergel http://i-base.info/htb/16049 2011 HIV Persistence Workshop http://i-base.info/htb/16047 A Call for Comprehensive Responses to HIV in People Who Use Drugs http://i-base.info/htb/16045 Achieving a cure for HIV infection: do we have reasons to be optimistic? http://i-base.info/htb/16041 2012 conference listing http://i-base.info/htb/101 Volume 13 Number 1/2 January/February 2012 PDF http://i-base.info/htb/16018 13th European AIDS Conference (EACS), Belgrade, Serbia, 12–15 October 2011 http://i-base.info/htb/15966 European guidelines (EACS) – 2011 update http://i-base.info/htb/15964 Raltegravir achieves superiority over efavirenz after four years http://i-base.info/htb/15961 Higher plasma levels of tenofovir and darunavir but not efavirenz in older patients http://i-base.info/htb/15959 Ritonavir levels reduced with high fat meal http://i-base.info/htb/15957 Transplacental transfer of raltegravir and delayed plasma clearance in preterm neonates http://i-base.info/htb/15955 2nd International Workshop on HIV and Ageing, Baltimore, Maryland, 27–28 October 2011 http://i-base.info/htb/15953